Video

The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer

Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Michael Jenson, PA-C, answers a question during a Zoom video interview
Couple talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
© 2025 MJH Life Sciences

All rights reserved.